View the article online at http://citywire.co.uk/money/article/a520974
AstraZeneca suffers setback as Crestor study fails to convince
Shares in AstraZeneca (AZN.L) fell today after the company revealed its best-selling cholesterol drug Crestor had failed to beat its main rival in a clinical study.
Shares in AstraZeneca (AZN.L) fell 2.8% today after the company revealed that its best-selling cholesterol drug Crestor had failed to beat its main rival in a clinical study.
Imaging tests in the ‘Saturn’ study commissioned by AstraZeneca showed that Crestor had a greater impact in reducing fatty deposits in arteries than Pfizer’s Lipitor drug. However, the company admitted the difference was not statistically significant.
AstraZeneca, viewed as a defensive stock that held up well in last month’s market falls, dropped 83p to £28.32 as analysts warned that the findings would prompt them to cut their earnings forecasts.
The comparison with Lipitor – the world’s biggest prescription drug – is significant because Pfizer’s patent expires in November. AstraZeneca wanted to stress Crestor’s superiority against forthcoming generic rivals from the likes of Ranbaxy and Watson in the US. Crestor is AstraZeneca’s top selling drug achieving $5.7 billion of sales last year.
The consensus of analyst forecasts is for Crestor sales of $7.1 billion by 2015. However, Naresh Chouhan of Liberum Capital, who is negative on the stock, predicted a 5% hit to 2015 earnings as a result of a lower contribution from Crestor.
Dr Mike Mitchell of Seymour Pierce stuck with his ‘reduce’ recommendation with a £28 price target. Although he noted that the full details of the study would not be available until November, the top-line findings had failed to demonstrate the clear benefit of Crestor, he said.
Navid Malik of Matrix also said ‘reduce’ with a £28.06 price target. ‘We see AZN as unable to offset the generic exposure it faces from patent expirations, ongoing poor delivery from its pipeline and an under-weighting in biological drugs.’
Analysts at Jefferies maintained a ‘hold’ with a price target of £26.
Savvas Neophytou of Panumre Gordon was more positive, saying establishing ‘any handle’ over Lipitor was an important step in protecting market share. He maintained a ‘buy’ recommendation and a target price of 36p.
AstraZeneca shares have fallen from £33.90 in the past year but are up from low of £24.53 on 9 August. It made £13 billion in pre-tax profits last year, forecast to fall to £12.7 billion according to data from Thomson Reuters. The shares currently trade on a prospective yield of 5.7% and are a key holding in many funds, including the Invesco Perpetual Income and High Income funds run by Neil Woodford.
Leading investors like Neil Woodford and our own Smart Investor like AstraZeneca for its strong balance sheet, resilient earnings and good dividend. While the news once again demonstrates the pressure on major pharmaceuticals to maintain a pipeline of new drugs, it is not a reason to give up on the stock's defensive qualities right now.
News sponsored by:
Making the most out of Europe’s potential means seeing things differently. Learn more about how BlackRock’s focused approach to investing in Europe helps investors unlock the continent’s vast potential.
In this guide to investment trusts, produced in association with Aberdeen Asset Management, we spoke to many of the leading experts in the field to find out more.
More about this:
Look up the funds
Look up the shares
Look up the fund managers
More from us
Tools from Citywire Money
From the Forums
Weekly email from The Lolly
Get simple, easy ways to make more from your money. Just enter your email address below
An error occured while subscribing your email. Please try again later.
Thank you for registering for your weekly newsletter from The Lolly.
Keep an eye out for us in your inbox, and please add firstname.lastname@example.org to your safe senders list so we don't get junked.
by Michelle McGagh on Oct 28, 2016 at 05:01